CD19 Human Recombinant Protein

CAT#: TP721365

Human CD19 Protein (C-Fc-Avi)

Product Images

Human CD19 Protein (C-Fc-Avi) on SDS-PAGE under reducing condition P(+) and non-reducing condition P(-). The purity of this protein appears to be greater than 95% based on Coomassie-blue staining.

Specifications

Product Data

• Species: Human
• Expression Host: CHO
• Expression cDNA Clone or AA Sequence:
  Protein Sequence

  Glu21-Lys291
• Tag: C-Fc-Avi
• Predicted MW: The protein has a predicted molecular weight of 58kDa and migrates at approximately 70-80kDa on SDS-PAGE with DTT-reduced condition.
• Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is bottled at lot specific concentration.
• Purity: >90%
• Presentation: Purified
• Buffer: 1xPBS buffer, pH7.4
• Bioactivity: Positive
  
  The definition of the active protein (purified and biotinylated) is defined as the protein that can bind to its biological receptor/ligand. For conjugated protein, it is defined with its function to bind to the ScFv of the active CAR-transfected cells in flow cytometry test.
• Preparation: Affinity Protein A
• Applications: ELISA
• Storage: An unopened vial can be stored at 4°C for 2 weeks or at -20°C and below for six months. This stock solution should be aliquoted and stored at ≤ -70°C to minimize the freeze/thaw cycles.
• Stability: 6 Months

Reference Data

• RefSeq: P15391
• Locus ID: 930
• UniProt ID: P15391
• Summary: CD19 is a single-pass type I membrane protein containing 2 Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. CD19 primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. CD19 Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) which is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.